EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS | Publicación